Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:48 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 242 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: oral intake Clear all

Conditions: Autism Spectrum Disorder, Autism
Interventions: Pregnenolone, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 14 Years to 25 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Stanford, California

Conditions: Healthy
Interventions: Dietary Supplement: Dietary supplement: Protein intake; Dietary Supplement
Lead sponsor: Arkansas Children's Hospital Research Institute; Other
Eligibility: 8 Years to 10 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Glioblastoma, Gliosarcoma
Interventions: Imatinib Mesylate & Hydroxyurea; Drug
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Type 2
Interventions: Oral Nutrition Supplement; Other
Lead sponsor: Société des Produits Nestlé (SPN); Industry
Eligibility: 20 Years to 75 Years
Enrollment: 14 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 1
States / cities: Tustin, California

Conditions: Glucose Transporter Type 1 Deficiency Syndrome
Interventions: UX007; Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 1 Year and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 5
States / cities: Aurora, Colorado • Miami, Florida • New York, New York + 2 more

Conditions: Nonalcoholic Fatty Liver Disease (NAFLD)
Interventions: intravenous fructose challenge, Blood Draw; Drug · Other
Lead sponsor: Manal F Abdelmalek; Other
Eligibility: 18 Years to 75 Years
Enrollment: 118 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2020
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction
Interventions: Bocidelpar, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Unilateral Vestibulopathy (AUV)
Interventions: SENS-111 100mg, SENS-111 200mg, Placebo Oral Tablet; Drug
Lead sponsor: Sensorion; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Conditions: Adenocarcinoma
Interventions: Bevacizumab, Capecitabine, Cisplatin, Placebo, 5-fluorouracil; Drug
Lead sponsor: Genentech, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 774 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 13
States / cities: Beverly Hills, California • La Jolla, California • Los Angeles, California + 9 more

Conditions: Pregnancy
Interventions: Folic acid, 400 mcg/day, Folic acid 800 mcg/day; Dietary Supplement
Lead sponsor: University of Georgia; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Athens, Georgia

Conditions: Hypertension
Interventions: fenofibrate, Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 75 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Diabetes Mellitus, Diabetic Ketoacidosis
Interventions: Early feeding with an oral diet; Other
Lead sponsor: Texas Tech University Health Sciences Center; Other
Eligibility: 18 Years to 89 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Lubbock, Texas

Conditions: Obesity
Interventions: Metformin, Dietary modification with caloric restriction, Establishment of exercise protocol; Drug · Behavioral
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 7 Years to 18 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2011
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Prostatic Neoplasms, Metastatic Castration-Resistant Prostate Cancer
Interventions: Abiraterone Acetate, Prednisone, JNJ-56021927; Drug
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 99 Years · Male only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2027
U.S. locations: 3
States / cities: Los Angeles, California • San Francisco, California • Houston, Texas

Conditions: Dental Cavity, Caries,Dental
Interventions: Nutritional Counseling; Behavioral
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Myelodysplastic Syndrome, MDS, Trisomy 8
Interventions: rigosertib; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2015
U.S. locations: 5
States / cities: Scottsdale, Arizona • Atlanta, Georgia • Rochester, Minnesota + 2 more

Conditions: Autism Spectrum Disorder
Interventions: STP1, Placebo; Drug
Lead sponsor: Stalicla SA; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Wild Type BRAF Stage IV Melanoma, Unresectable Stage III Melanoma
Interventions: TMZ, E7016; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Anxiety, Pain, Surgery
Interventions: Galacto-Oligosaccharide, Maltodextrin (Placebo); Drug
Lead sponsor: Jeff Taekman, M.D.; Other
Eligibility: 21 Years to 70 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Dry Mouth
Interventions: Marketed Dry Mouth Rinse, Water control, Experimental Dry Mouth Rinse; Device · Other
Lead sponsor: Procter and Gamble; Industry
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Mason, Ohio

Conditions: Diabetes, PreDiabetes
Interventions: Oral application of miracle fruit pill, Oral application of sugar candy; Other
Lead sponsor: Queens College, The City University of New York; Other
Eligibility: 45 Years to 75 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Bayside, New York

Conditions: Frailty, Functional Recovery, Prehabilitation
Interventions: Exercise, Nutrition, Meditation, Cognitive Behavioral Intervention; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Basic Science, Intervention Studies, Biomarker Discovery
Interventions: Oral Lozenges (Tradename pHossident), Water additive (Tradename Protektin); Dietary Supplement
Lead sponsor: Delta Dental of Minnesota Foundation; Other
Eligibility: 18 Years to 80 Years
Enrollment: 595 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Atherosclerosis
Interventions: Statin therapy, Lifestyle modification; Drug · Behavioral
Lead sponsor: Emory University; Other
Eligibility: 22 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2017
U.S. locations: 1
States / cities: Atlanta, Georgia

Search by objective public record fields.

Pilot Trial of Pregnenolone in Autism

Protein Requirements for Active Children

Phase II Imatinib + Hydroxyurea in Treatment of Patients With Recurrent/Progressive Grade II Low-Grade Glioma (LGG)

Glycemic Response in Persons With Type 2 Diabetes Mellitus

Study to Assess the Long Term Safety and Efficacy of UX007 in Participants With Glucose Type 1 Deficiency Syndrome (Glut1 DS)

Impact of Fructose on Metabolism, Energy Homeostasis and Magnetic Resonance Biomarkers in Nonalcoholic Fatty Liver Disease

A Study to Evaluate ASP0367 in Participants With Reduced Maximum Oxygen Uptake Due to Poor Systemic Oxygen Extraction

Efficacy of SENS-111 in Patients Suffering From Acute Unilateral Vestibulopathy

A Study of Bevacizumab in Combination With Capecitabine and Cisplatin as First-line Therapy in Patients With Advanced Gastric Cancer

Folic Acid Supplementation in Pregnant Women: Dose Response

The Effect of a Peroxisome Proliferator-activated Receptor (PPAR) Alpha Agonist on Cytochrome P450 (CYP) Monooxygenase Activity in Humans

Starvation in the Treatment of Diabetic Ketoacidosis

Study of Serum Markers for Cardiovascular Risk in Obese Youth and Impact of Lifestyle and Medication Intervention

A Study of JNJ-56021927 (ARN-509) and Abiraterone Acetate in Participants With Metastatic Castration-Resistant Prostate Cancer

Effectiveness of a Nutritional Counseling Tool in Reducing the Amount and Frequency of Sugar Intake

Efficacy and Safety of Oral Rigosertib in Transfusion-dependent, Low or Int-1 or Trisomy 8 Int-2 Myelodysplastic Syndrome

Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)

Phase 2 Study of the Poly(ADP-Ribose) Polymerase Inhibitor E7016 in Combination With Temozolomide in Subjects With Wild Type BRAF Stage IV or Unresectable Stage III Melanoma

Exploring the Impact of Perioperative Galacto-Oligosaccharides (GOS) on Stress, Anxiety and Cognition

A Pilot Study to Assess Dry Mouth Relief After Using an Experimental Mouth Rinse

Effects of Miracle Fruit Pill Application on Food Likings and Energy Intake in Diabetic or Prediabetic Patients

Multi-Component Prehabilitation for Major Elective Surgery

Comprehensive Multi-omics Characterization and Implications of Non-Pharmaceutical Dental Hygiene Product in a Randomized Controlled Large Population Study.

Accelerated Atherosclerosis in High Risk Population Groups: An Assessment by Magnetic Resonance Imaging